Politics of Cuban Medical Innovation and the US Embargo: The Case of Heberprot-P
Describe the ways the US Economic embargo blocks access by Americans to Cuban pharmaceutical products that could offer tangible benefits. Explain how this has prevented clinical testing of Heberprot-P in particular.
Qualified on the content I am responsible for because: I am the Executive Director of Medical Education Cooperation with Cuba (MEDICC) and have over 30 yearsâ experience in NGO leadership. The scope of my expertise encompasses academic research, policy analysis, advocacy, strategic communications and publishing, as well as resource development.
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.